Диссертация (1174357), страница 25
Текст из файла (страница 25)
Ewies, P. Musonda // Eur. J. Obstet. Gynecol. Reprod. Biol. –2010. – Vol. 153 (1). – P. 67-71.190. Expressionof estrogen andprogesterone receptor subtypesinhumanendometrial carcinoma tissues / Q.P. Liao [et al.] // Zhonghua Fu Chan Ke Za Zhi. –2005. – Vol. 40 (11). – P. 752-755.191. Expression of estrogen receptors alpha and beta, and progesterone receptorsA and B in human mucinous carcinoma of the endometrium / N. Shabani [et al.] //Anticancer Res.
– 2007. – Vol. 27 (4A). – P. 2027-2033.192. Expression of estrogen receptor-alpha and -beta and progesterone receptor-Aand -B in a large cohort of patients with endometrioid endometrial cancer / V. Jongen[et al.] // Gynecol. Oncol. – 2009. – Vol. 112 (3). – P. 537-542.193. Expression of estrogen receptor-related receptor isoforms and clinicalsignificance in endometrial adenocarcinoma / M. Gao [et al.] // Int.
J. Gynecol. Cancer.– 2006. – Vol. 16 (2). – P. 827-833.194. Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, inendometrial cancers and evidence that prostaglandin F may play a role in regulatingexpression of ERalpha / F. Collins [et al.] // BMC Cancer. – 2009. – Vol. 9. – P. 330.158195. Expression of receptor-binding cancer antigen expressed on SiSo cellsand estrogen receptor subtypes in the normal, hyperplastic, and carcinomatousendometrium / X.H.
Zhou [et al.] // Int. J. Gynecol. Cancer. – 2008. – Vol. 18 (1). – P.152-158.196. Expression of tubulin, p53, ki67, receptors for estrogen, and progesteronein endometrial cancer / C. Zhu [et al.] // Eur. J. Gynaecol. Oncol. – 2009. – Vol. 30 (5).– P. 514-517.197. Fertility-sparing treatment in young women with endometrial cancer oratypical complex hyperplasia: a prospective single-institution experience of 21 cases /M. Signorelli [et al.] // Br. J. Obstet. Gynecol. – 2009. – Vol. 116 (1).
– P. 114-118.198. Fleenor D. Growth hormone and prolactin receptors in adipogenesis: STAT5 activation, suppressors of cytokine signaling, and regulation of insulin-like growthfactor I / D. Fleenor, R. Arumugam, M. Freemark // Horm. Res. – 2006. – Vol. 66 (3). –P. 101–110.199. Fleenor, D.E. Prolactin induction of insulin gene transcription: roles ofglucose and signal transducer and activator of transcription 5 / D.E. Fleenor, M.Freemark // Endocrinology. – 2001. – Vol.
142 (7). P. 2805–2810.200. Focus on prolactin as a metabolic hormone / Ben-Jonathan N. [et al.] //Trends Endocrinol. Metab. – 2006. –Vol. 17 (3). – P. 110–116.201. Further studies on th eantigonadotropic mechanism of action ofnorethisterone / J. Garza-Flores [et al.] // J. Steroid Biochem.
Mol. Biol. – 1991. – Vol.38 (1). – P. 89-93.202. Genetic alterations in endometrial hyperplasia and cancer / G. Fabjani [et al.]// Cancer Lett. – 2002. – Vol. 175 (2). – P. 205-211.203. Global cancer statistics / A. Jemal [et al.] // CA Cancer J. Clin. – 2011. –Vol. 61 (2). – P. 69-90.204.
Global gene profiling in human endometrium during the window ofimplantation / L.C. Kao [et al.] // Endocrinology. – 2002. – Vol. 143 (6). – P. 21192138.159205. Goletiani, N. V. Progesterone : review of safety for clinical studies / N.V.Goletiani, D.R. Keith, S.J. Gorsky // Exp. Clin.
Psychopharmacol. – 2007. – Vol. 15 (5).– P. 427-444.206. Goncharenko, V.M. Predictive diagnosis of endometrial hyperplasia andpersonalized therapeutic strategy in women of fertile age / V.M. Goncharenko, V.A.Beniuk, O.V. Kalenska // EPMA J. – 2013. – Vol. 4 (1). – P. 24.207. GPR30: a novel indicator of poor survival for endometrial carcinoma / H.O.Smith [et al.] // Am.
J. Obstet. Gynecol. – 2007. Vol. 196 (4). – P. 386.e1-e9.208. Grady, D. Hormone replacement therapy and endometrial cancer: are currentregimens safe? / D. Grady, V.L. Ernster // J. Natl. Cancer Inst. – 1997. – Vol. 98. – P.1088-1089.209. Grattan, D.R. Prolactine: a pleirotropic neuroendocrine hormone / D.R.Grattan, I.C. Kokay // J. Neuroendocrinol. – 2008. – Vol. 20 (6). – P. 752-763.210. Gunin, A.G. Proliferation, mitosis orientation and morphogenetic changes inthe uterus of mice following chronic treatment with both estrogen and glucocorticoidhormones / A.G. Gunin, I.N.
Mashin, D.A. Zakharov // J. Endocrinol. – 2001. – Vol.169 (1). – P. 23-31.211. Gustafsson, J.A. ERbeta scientific visions translate to clinical uses / J.A.Gustafsson // Climacteric. – 2006. – Vol. 9 (3). – P. 156-160.212. Gynecologic conditions in participants in the NSABP breast cancerprevention study of tamoxifen and raloxifene (STAR) / C.D. Runowicz [et al.] //American Journal of Obstetrics Gynecology.
– 2011. – Vol. 205 (6). – P. 535 e1–535e5.213. Hannemann, M.M. Endometrial hyperplasia: a clinician’s review / M.M.Hannemann, H.M. Alexander, N.J. Cope // Obstet. Gynecol. Reprod. Med. – 2010. –Vol. 20 (4). – Р. 116-120.214. Hapangama, D. Estrogen receptor β: the guardian of the endometrium / D.Hapangama, A. Kamal, J. Bulmer // Human Reproduction Update. – 2014. – Vol. 21(2).
– P. 174-193.160215. Harris, C.C. The 1995 Walter Hubert Lecture--molecular epidemiology ofhuman cancer: insights from the mutational analysis of the p53 tumour-suppressor gene/ C.C. Harris // Br. J. Cancer. – 1996. – Vol. 73 (3). – P. 261-269.216. Heil, S.H.
Sex-specific effects of prolactin on food intake by rats / S.H. Heil// Horm. Behav. – 1999. – 35 (1). – Р. 47-54. Heterogeneity in endometrial expressionof aromatase in polyp-bearing uteri / L. Pal [et al.] // Hum. Reprod. – 2008. – Vol. 23(1). – P. 80-84.217. Hormone receptor expressions and proliferation markers in postmenopausalendometrial polyps / U.S. Inceboz [et al.] // Gynecol.
Obstet. Invest. – 2006. – Vol. 61(1). – P. 24-28.218. Hu, K. Expression of estrogen receptors ERalpha and ERbeta in endometrialhyperplasia and adenocarcinoma / K. Hu, G. Zhong, F. He // Int. J. Gynecol. Cancer. –2005. – Vol. 15 (3). – P. 537-541.219. Hu, R. Molecular mechanisms of tamoxifen-associated endometrial cancer. /R. Hu, L.
Hilakivi-Clarke, R. Clarke // Oncology Letters. – 2015. – Vol. 9 (4). –P.1495-1501.220. Hyperprolactinemia stimulates food intake in the female rat / Moore B.J. [etal.] // Brain Res. Bull. – 1986. – Vol. 17 (4). – P. 563–569.221. Hysteroscopic dynamic assessment of the endometrium in patients treatedwith long-term tamoxifen / T. Pérez-Medina [et al.] // The Journal of MinimallyInvasive Gynecology. – 2011.
– Vol. 18 (3). – P. 349–354.222. Immunohistochemical analysis of c-myc, c-jun and estrogen receptor innormal, hyperplastic and neoplastic endometrium / S. Bircan [et al.] // Pathol. Oncol.Res. – 2005. – Vol. 11 (1). – P. 32-39.223. Incidence of endometrial hyperplasia / S.D. Reed [et al.] // Am. J.
Obstet.Gynecol. – 2009. – Vol. 200 (6). – Р. 678.e1-6.224. Inflammation and endometrial cancer: a hypothesis / F. Modugno [et al.] //Cancer Epidemiol. Biomarkers Prev. – 2005. – Vol. 14 (12). – P. 2840–2847.161225. Inflammatory bowel disease and celiac disease: Overlaps in the pathologyand genetics, and their potential drug targets / E.A.M. Festen [et al.] // Endocr. Metab.Immune Disord. Drug Targets.
– 2009. – Vol. 9 (2). – P. 199-218.226. Is diabetes mellitus associated with increased incidence and disease-specificmortality in endometrial cancer? A systematic review and meta-analysis of cohortstudies / C. Liao [et al.] // Gynecol. Oncol. – 2014. – Vol. 135 (1). – P.
163-171.227. Immunohistochemical analysis of c-myc, c-jun and estrogen receptor innormal, hyperplastic and neoplastic endometrium / S. Bircan [et al.] // Pathology &Oncology Research. – 2005. – Vol. 11 (1). – P. 32-39.228. Immunohistochemicalanalysisofestrogen receptor alpha,estrogen receptor beta and progesterone receptor in normal human endometrium / I.Mylonas [et al.] // Acta Histochem. – 2004. – Vol. 106 (3). – P.
245-252.229. Immunohistochemical expression of estrogen and progesterone receptors inendometrial polyps and adjacent endometrium in postmenopausal women / E.C.Sant’Ana de Almeida [et al.] // Maturitas. – 2004. – Vol. 49 (3). – P. 229-233.230. Immunohistochemical labeling of steroid receptors in normal and malignanthuman endometrium / I.
Mylonas [et al.] // Acta Histochem. – 2009. – Vol. 111 (4). – P.349-359.231. International Union of Pharmacology. LXIV. Estrogen receptors / K.Dahlman-Wright [et al.] // Pharmacol. Rev. – 2006. – Vol. 58 (4). – P. 773-781.232. Iram, S. Premenopausal bleeding: When should the endometrium beinvestigated? A retrospective non-comparative study of 3006 women / S.
Iram, P.Musonda, A.A. Ewies // Eur. J. Obstet. Gynecol. Reprod. Biol. – 2010. – Vol. 148 (1). –P. 86-89.233. Ismail, M. T. Efficacy of levonorgestrel-releasing intrauterine system versusoral progestins in treatment of simple endometrial hyperplasia without atypia / M.
T.Ismail, D. M. Fahmy, N. S. Elshmaa // Reprod. Sci. – 2013. – Vol. 20 (1). – P. 45-50.234. Katzenellenbogen, B.S. Estrogen receptors: bioactivities and interactionswith cell signaling pathways / B.S. Katzenellenbogen // Biol. Reprod. – 1996. – Vol. 54(2). – P. 287-93.162235. Keator, C.S. Alterations in progesterone receptor membrane component 2(PGRMC2) in the endometrium of macaques afflicted with advanced endometriosis /C.S. Keator, K. Mah, O. D. Slayden // Mol. Hum. Reprod. – 2012. – Vol.
18 (6). – P.308-319.236. Kerr, J.F. Apoptosis: A basic biological phenomenon with wide-rangingimplications in tissue kinetics / J.F. Kerr, A.H. Wyllie, A.R. Currie // Br. J. Cancer –1972. – Vol. 26 (4). – P. 239-257.237. Kim, J. J. Role of Progesterone in Endometrial Cancer / J. J.
Kim, E.Chapman-Davis // Semin. Reprod. Med. – 2010. – Vol. 28 (1). – P. 81-90.238. Kurman, R.J. Evaluation of criteria for distinguishing atypical endometrialhyperplasia from well-differentiated carcinoma / R.J. Kurman, H.J. Norris // Cancer. –1982. – Vol. 49 (12). – Р. 2547-59.239. Kurman, R.J. Endometrial hyperplasia and related cellular changes.Blaustein’s pathology of the female genital tract, – 5 ed. / Ed. Kurman R.J.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
